$emis $
"72% of people treated with semaglutide hit the ada target of hba1c below 7% , while only 47% of patients on empagliflozin hit this target"
racing to grab market share in diabetes, novo touts its oral ozempic win over jardiance in phiiia trial - https://t.co/vyiaveuech